spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  non-Hodgkin’s lymphoma 

 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Oct 2016
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jul 2016
Genentech Provides Update on Phase III Study of Gazyva(R) in People With Previously Untreated Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jul 2016
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Dec 2015
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2015
Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jan 2014
Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 1 Nov 2013
FDA Approves Gazyva (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Oct 2013
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 Jul 2013
FDA Grants Genentech’s Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Nov 2012
ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jul 2012
Biovest Advances Process Seeking European Marketing Approval for BiovaxID(TM) Personalized Lymphoma Vaccine
Biopharmaceuticals Oncology Personalized Medicine
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons
 HSMN NewsFeed - 27 Jan 2012
Spectrum Pharmaceuticals Strengthens Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jan 2012
Celgene to Acquire Avila Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jun 2011
Nimbus Discovery Secures $24 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 May 2011
Yaupon Therapeutics Names Steve Tullman Chairman and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Feb 2011
Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 5 Jan 2011
Spectrum Pharmaceuticals to Develop Biosimilar Rituximab
Biopharmaceuticals Oncology Generics
 HSMN NewsFeed - 29 Nov 2010
Accentia Biopharmaceuticals Announces Strategic Agreement with Baxter
Biopharmaceuticals
 HSMN NewsFeed - 19 Jul 2010
Spectrum Pharmaceuticals Appoints George Tidmarsh, M.D., Ph.D, as Senior Vice President, Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2010
Calistoga Pharmaceuticals Raises $40 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Jun 2010
Accentia Files Plan of Reorganization
Biopharmaceuticals Neurology
 HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2009
Celgene to Acquire Gloucester Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 15 Dec 2008
FDA Approves Genzyme's Mozobil
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biopharmaceuticals
 HSMN NewsFeed - 22 Apr 2008
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2008
Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2008
Biovest Reports that Independent Data Monitoring Committee Recommends Unblinding of Phase 3 Clinical Results for its Anti-Cancer Vaccine, BiovaxID(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Mar 2008
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
Biopharmaceuticals
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.